SEC Tracker
Get the app

8-KARQT

Arcutis reports Q3 2026 results

ZORYVE net product sales for the third quarter of 2026 were $143.9 million, reflecting 45% year-over-year growth and an 11% sequential increase versus the second quarter of 2026.1

By SEC Tracker ·

Arcutis BiotherapeuticsCIK 1787306Form 8-KFiled Nov 4, 2026, 4:03 PM ET0001787306-26-000056Read the filing on SEC.gov →

The company raised its 2026 full-year net product sales guidance to $535 million–$545 million.2 It also reported $18.9 million of net cash provided by operating activities for the quarter.3

Arcutis announced the launch of the Skin to Believe In campaign with Simone Biles to raise awareness of inflammatory skin conditions.4 The company also appointed new leadership, including Rob Lisicki as chief commercial officer and Rob Scott, MD, to the Board of Directors.5

Key facts

Company
Arcutis Biotherapeutics (ARQT)
CIK
1787306
Form
8-K
Items
2.02, 9.01
Filed
Nov 4, 2026, 4:03 PM ET
Accession
0001787306-26-000056

From the EDGAR filing index, not written by AI.

Arcutis Biotherapeutics results from its filings

Revenue, net income and cash as tagged in XBRL in the company's 10-Q and 10-K filings, up to this filing. Drawn in code; no figure here is written by AI.

Arcutis Biotherapeutics revenue and net income by quarterRevenueNet income$ millionsSource: XBRL in the company's 10-Q and 10-K filings, SEC EDGAR050100150Revenue · Q2 FY26: 129.9129.9Net income · Q2 FY26: 15.015.0Revenue · Q3 FY26: 143.9143.9Net income · Q3 FY26: 8.88.8Q2 FY26Q3 FY26
Arcutis Biotherapeutics cash at period end$ millionsSource: XBRL in the company's 10-Q and 10-K filings, SEC EDGAR01020304033.4Q2 FY26Q3 FY26Cash · Q2 FY26: 34.1Cash · Q3 FY26: 33.4
The numbers
PeriodRevenueNet incomeCashFiling
Q1 FY24———10-Q/A
Q2 FY26$129.9M$15.0M$34.1M10-Q
Q3 FY26$143.9M$8.8M$33.4M10-Q

How often Arcutis Biotherapeutics files

Filings per calendar quarter, counted in code from the company's EDGAR filing list. Each bar splits 8-K current reports from other forms; the last bar is the quarter of this filing, counted up to it.

Arcutis Biotherapeutics filings per quarter8-KOther formsSource: EDGAR filing list, counted in code02040608-K · Q1 25: 2Other forms · Q1 25: 348-K · Q2 25: 3Other forms · Q2 25: 448-K · Q3 25: 1Other forms · Q3 25: 338-K · Q4 25: 2Other forms · Q4 25: 498-K · Q1 26: 1Other forms · Q1 26: 398-K · Q2 26: 2Other forms · Q2 26: 388-K · Q3 26: 2Other forms · Q3 26: 298-K · Q4 26: 2Other forms · Q4 26: 173647345140403119Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26
Arcutis Biotherapeutics filings per quarter
The numbers
QuarterFilings8-K
Q1 25362
Q2 25473
Q3 25341
Q4 25512
Q1 26401
Q2 26402
Q3 26312
Q4 26192

Timeline

The company's filings on EDGAR around this one, newest first. Ownership forms and routine prospectus filings are left out.

  1. Form 8-KThis filing
  2. Form 10-Q
  3. Form 8-K
  4. Form 10-Q
  5. Form 8-K
  6. Form 8-K

Get an email when Arcutis Biotherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Written with AI from the Arcutis Biotherapeutics Form 8-K and checked against it sentence by sentence: each of the 5 numbered sentences opens the passage it comes from. AI can make mistakes. Check the filing. Not investment advice. Not affiliated with the U.S. SEC. Source filing on SEC.gov.

Data on this page was fetched . The filing on SEC.gov is the record.